The major autoantibody target, found in approximately 85% of myasthenia gravis patients, is the extracellular N-terminal region of the alpha 1 subunit of the nicotinic acetylcholine receptor/nAChR (CHRNA1), which is highly enriched in skeletal muscle (Figure 2A). The gene discussed is CHRNA1; the disease is myasthenia gravis.